Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
What the film says
The deadliest childhood brain tumors, diffuse midline gliomas, carry a surface molecule called GD2. Immune cells engineered to hunt GD2 can find them, but they tire and fade before the job is done.
The idea: give the hunters a built-in supply of the signal that keeps T cells alive.
A child's own T cells get two genes. One is a receptor for GD2. The other, C7R, is a permanently switched-on receptor for interleukin-7, the survival signal T cells normally need from outside.
In the first eleven children there were no dose-limiting side effects, and two of seven gliomas shrank.
GAIL-B, at Texas Children's with Jasia Mahdi and Bilal Omer, now gives the cells into the fluid around the brain. Public record; not medical advice.
Sources behind this film
Mount CW. Nat Med, 2018
Diffuse midline gliomas carry GD2; GD2 CAR T cells can find them but fade
Diffuse midline gliomas carry GD2; GD2 CAR T cells can find them but fade; Two genes: GD2 CAR plus C7R, a constitutively active IL-7 receptor; Now intracerebroventricular dosing via Ommaya, finding the safe dose; GAIL-B, Texas Children's, Jasia Mahdi and Bilal Omer
Lin FY. J Clin Oncol, 2024
Two genes: GD2 CAR plus C7R, a constitutively active IL-7 receptor; Eleven children, no dose-limiting toxicity; temporary neurologic improvement (2 to >12 months); partial responses in two of seven DMG
The drug
Dose levels administered are by IV infusion followed by ICV infusion. Cycle 1: 20 million cells/m2 delivered IV with lymphodepletion. Cycle 2 (and subsequent cycles): Dose level 1: 5 million cells ICV with lymphodepletion.
To prepare the brain cancer specific GD2-C7R T cells, research staff will take some blood from the patient. The researchers will grow the GD2.C7R T cells by infecting the T cells with a retroviral vector (a special virus that can carry a new gene into cells) containing one gene that can recognize and kill brain cancer cells GD2.CAR and the new gene called C7R that will help these cells survive longer.
After the new genes have been put into the T cells, the cells will be tested to make sure that they kill GD2-positive brain cancer cells. All patients on this study are required to have an Ommaya catheter in place prior to treatment as a precaution and for infusion of the T cells. This is a special catheter that leads to the tumor, the cavity left in the brain after surgical removal of the tumor, or into the fluid-filled space in the brain.
The study
In this study, there are two treatment groups called Cohort 1 and Cohort 2. Cohort 1 is for patients with diffuse midline glioma, diffuse intrinsic pontine glioma, medulloblastoma, or another rare high-grade glioma that expresses GD2. Cohort 2 is for patients with a type of cancer called progressive diffuse intrinsic pontine glioma that expresses GD2.
Because there is no standard treatment at this time, patients are asked to volunteer in a gene transfer research study using special immune cells called T cells. T cells are a type of white blood cell that help the body fight infection. This research study combines two different ways of fighting cancer: antibodies and T cells. Both antibodies and T cells have been used to treat cancer patients. They have shown promise but have not been strong enough to cure most patients.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.